You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Schematic description of clinical outcomes according to MIC, genotype, age, Charlson comorbidity index (CCI), presence of concomitant bacteremia and septic shock in cefepime, piperacillin/tazobactam and ertapenem groups

From: Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

Case MIC (μg/mL) ESBLs genotype CCI Bacteremia Septic shock Clinical outcome
A. Cefepime (N = 6)
 Patient 1 2 CTX-M-14 5 No No Success
 Patient 2 2 CTX-M-14 3 No No Success
 Patient 3 1 CTX-M-14 4 No No Failure
 Patient 4 2 CTX-M-14 6 No No Failure
 Patient 5 1 SHV-12 5 No Yes Failure and expired
 Patient 6 2 CTX-M-14 5 No Yes Failure and expired
B. Piperacillin/tazobactam (N = 33)
 Patient 1 4 CTX-M-14 6 No No Success
 Patient 2 4 CTX-M-15 5 No Yes Success
 Patient 3 4 CTX-M-15 0 No No Success
 Patient 4 4 CTX-M-15 1 No No Success
 Patient 5 4 CTX-M-27 9 No No Success
 Patient 6 4 CTX-M-27 9 No No Success
 Patient 7 4 CTX-M-27 9 No No Success
 Patient 8 8 CTX-M-14 3 Yes Yes Success
 Patient 9 8 CTX-M-14 1 No No Success
 Patient 10 16 CTX-M-1 4 No No Success
 Patient 11 16 CTX-M-3 2 No Yes Success
 Patient 12 16 CTX-M-14 3 No No Success
 Patient 13 16 CTX-M-14 3 Yes Yes Success
 Patient 14 16 CTX-M-15 1 No Yes Success
 Patient 15 16 CTX-M-15 4 No No Success
 Patient 16 16 CTX-M-27 0 No No Success
 Patient 17 16 CTX-M-15 3 No No Success
 Patient 18 16 CTX-M-14 5 No No Success
 Patient 19 16 CTX-M-14 7 No No Success
 Patient 20 16 CTX-M-14 1 Yes No Success
 Patient 21 16 CTX-M-14 8 No No Success
 Patient 22 16 Not tested 5 No No Success
 Patient 23 16 Not tested 2 No Yes Success
 Patient 24 16 Not tested 7 No No Success
 Patient 25 16 Not tested 3 No No Success
 Patient 26 16 Not tested 7 No No Success
 Patient 27 16 Not tested 8 No No Success
 Patient 28 16 Not tested 5 No No Success
 Patient 29 16 Not tested 5 No No Success
 Patient 30 16 Not tested 3 Yes No Success
 Patient 31 16 Not tested 7 Yes Yes Success
 Patient 32 16 CTX-M-15 9 Yes Yes Failure and expired
 Patient 33 16 CTX-M-27 10 No Yes Failure and expired
C. Ertapenem (N = 33)
 Patient 1 0.5 CTX-M-15 0 No No Success
 Patient 2 0.5 CTX-M-27 0 No No Success
 Patient 3 0.5 CTX-M-14 1 No No Success
 Patient 4 0.5 CTX-M-15 1 No No Success
 Patient 5 0.5 CTX-M-14 1 Yes No Success
 Patient 6 0.5 CTX-M-15 1 No Yes Success
 Patient 7 0.5 CTX-M-3 2 No Yes Success
 Patient 8 0.5 CTX-M-14 2 Yes Yes Success
 Patient 9 0.5 CTX-M-14 3 No No Success
 Patient 10 0.5 CTX-M-15 3 No No Success
 Patient 11 0.5 CTX-M-15 3 No No Success
 Patient 12 0.5 CTX-M-14 3 Yes No Success
 Patient 13 0.5 CTX-M-14 3 Yes Yes Success
 Patient 14 0.5 CTX-M-14 3 Yes Yes Success
 Patient 15 0.5 CTX-M-1 4 No No Success
 Patient 16 0.5 CTX-M-15 4 No No Success
 Patient 17 0.5 CTX-M-14 5 No No Success
 Patient 18 0.5 CTX-M-14 5 No No Success
 Patient 19 0.5 CTX-M-15 5 No No Success
 Patient 20 0.5 CTX-M-14 5 Yes No Success
 Patient 23 0.5 CTX-M-15 5 No Yes Success
 Patient 21 0.5 CTX-M-14 6 Yes No Success
 Patient 22 0.5 CTX-M-14 7 No No Success
 Patient 24 0.5 CTX-M-14 7 No No Success
 Patient 25 0.5 CTX-M-14 7 No No Success
 Patient 26 0.5 CTX-M-14 8 No No Success
 Patient 27 0.5 CTX-M-14 8 No No Success
 Patient 28 0.5 CTX-M-27 9 No No Success
 Patient 29 0.5 CTX-M-27 9 No No Success
 Patient 30 0.5 CTX-M-27 9 No No Success
 Patient 31 0.5 CTX-M-27 10 No No Success
 Patient 32 0.5 CTX-M-14 9 Yes Yes Failure and expired
 Patient 33 0.5 CTX-M-15 7 Yes Yes Failure and expired
  1. Not tested: The isolate was ESBLs-positive by Vitek-2 system but not tested the ESBLs genotyping due to loss of the isolate